Livzon Pharmaceutical Group Inc.
000513
Classifica tra le azioni
#4689
Livzon Pharmaceutical Group Inc., headquartered in Zhuhai, China, and... Livzon Pharmaceutical Group Inc., headquartered in Zhuhai, China, and established in 1985, is a biopharmaceutical enterprise operating across the entire spectrum of pharmaceutical activities, from research and development to manufacturing and commercialization. The company's operations encompass a diverse range of finished drug products, active pharmaceutical ingredients (APIs), and chemical intermediates, primarily serving the Chinese market while also engaging in international exports. Its pharmaceutical portfolio includes treatments such as Ilaprazole enteric coated tablets for duodenal ulcers and reflux esophagitis, Laprazole sodium injection for managing peptic ulcer bleeding, Leuprorelin Acetate Microspheres for injection, and Urofollitropin injection for anovulation and fertility support. Livzon also produces Perospirone Hydrochloride for schizophrenia, Anti-viral Granules targeting upper respiratory tract infections and influenza, and Shenqi Fuzheng Injection, which addresses general weakness, fatigue, spontaneous sweating, and vertigo, and provides supportive care for lung and stomach cancer patients. Beyond therapeutic drugs, Livzon Pharmaceutical Group develops and distributes a variety of diagnostic reagents. These include kits for detecting IgM/IgG antibodies to coronavirus, nucleic acid tests for human immunodeficiency virus type 1, antinuclear antibody test kits, interferon-gamma release assay kits, and rapid tests for mycoplasma pneumoniae IgM antibodies. The company's extensive offerings further extend to biochemical drugs, microbiological preparations, biologics, traditional Chinese medicine formulations, pharmaceutical raw materials, and antibiotics.
Prezzo delle azioni
$3.90
Capitalizzazione di mercato
$3.17B
Variazione (1 giorno)
-3.49%
Variazione (1 anno)
-25.88%
Paese
CN
Scambia Livzon Pharmaceutical Group Inc. (000513)
Categoria
Healthcare
Margine operativo per Livzon Pharmaceutical Group Inc. (000513)
Margine operativo al October 2026 TTM: 20.23%
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Livzon Pharmaceutical Group Inc., il margine operativo attuale (TTM) è 20.23%. Alla fine del 2024, il margine operativo era 24.08%.
Storico del margine operativo per Livzon Pharmaceutical Group Inc. da 2001 a 2026
Margine operativo alla fine di ogni anno
| Anno | Margine Operativo | Cambia |
|---|---|---|
| 2026 (TTM) | 20.23% | -8.17% |
| 2025 | 22.03% | -8.51% |
| 2024 | 24.08% | 23.93% |
| 2023 | 19.43% | 4.41% |
| 2022 | 18.61% | -0.96% |
| 2021 | 18.79% | -20.95% |
| 2020 | 23.77% | 28.97% |
| 2019 | 18.43% | 28.16% |
| 2018 | 14.38% | -78.32% |
| 2017 | 66.32% | 475.69% |
| 2016 | 11.52% | 10.13% |
| 2015 | 10.46% | -0.76% |
| 2014 | 10.54% | -17.59% |
| 2013 | 12.79% | 4.84% |
| 2012 | 12.20% | -10.23% |
| 2011 | 13.59% | -28.25% |
| 2010 | 18.94% | -15.71% |
| 2009 | 22.47% | 36.02% |
| 2008 | 16.52% | -2.02% |
| 2007 | 16.86% | 123.61% |
| 2006 | 7.54% | -6.91% |
| 2005 | 8.10% | 2.40% |
| 2004 | 7.91% | -9.81% |
| 2003 | 8.77% | 22.66% |
| 2002 | 7.15% | -7.50% |
| 2001 | 7.73% | 0.00% |
Margine operativo per aziende simili o concorrenti
| Azienda | Margine Operativo | Differenza del margine operativo | Il paese |
|---|---|---|---|
| 19.41% | -99.04% |
DE
|
|
| 19.68% | -99.03% |
DE
|
|
| 10.52% | -99.48% |
JP
|
|
| 17.08% | -99.16% |
CH
|
|
| 22.93% | -98.87% |
IN
|
Cos'è l'Margine operativo di un'azienda?
L'Margine operativo è un indicatore chiave per valutare la redditività di un'azienda. Margini operativi più elevati sono generalmente preferibili poiché indicano che l'azienda riesce a vendere i propri prodotti o servizi a un prezzo significativamente superiore rispetto ai costi di produzione. Si calcola dividendo gli utili per i ricavi.